Tatsuta Takeo, Sugawara Shigeki, Takahashi Kohta, Ogawa Yukiko, Hosono Masahiro, Nitta Kazuo
Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Pharmaceutical University , Sendai , Japan.
Divisions of Functional Morphology and Microbiology, Department of Pharmacy, Faculty of Pharmaceutical Science, Nagasaki International University , Sasebo , Japan.
Front Oncol. 2014 Jun 4;4:139. doi: 10.3389/fonc.2014.00139. eCollection 2014.
Sialic acid-binding lectin (SBL) is a multi-functional protein that is isolated from oocytes of Rana catesbeiana. It has both lectin and ribonuclease (enzyme) properties, and therefore is called leczyme. We examined the anti-tumor effects of SBL and discovered that SBL has potential as a new type of anti-cancer drug. SBL causes a cancer-selective induction of apoptosis by multiple signaling pathways whereby RNA is its target. It is suggested that the mitochondrial pathway and endoplasmic reticulum stress-mediated pathway participate in SBL-induced signaling. The synergistic anti-tumor effects with other molecules, such as tumor necrosis factor-related apoptosis ligand and interferon γ, have been reported. In this study, we summarize the effects of SBL and focus on its cancer-selective apoptotic properties. In addition, we present a possible explanation for its cancer specificity.
唾液酸结合凝集素（SBL）是一种从牛蛙卵母细胞中分离出来的多功能蛋白质。它同时具有凝集素和核糖核酸酶（酶）的特性，因此被称为凝集酶。我们研究了SBL的抗肿瘤作用，发现SBL有潜力成为一种新型抗癌药物。SBL通过多种信号通路导致癌症选择性凋亡诱导，其中RNA是其靶点。提示线粒体途径和内质网应激介导的途径参与了SBL诱导的信号传导。已有报道称其与其他分子，如肿瘤坏死因子相关凋亡配体和干扰素γ具有协同抗肿瘤作用。在本研究中，我们总结了SBL的作用，并着重关注其癌症选择性凋亡特性。此外，我们对其癌症特异性提出了一种可能的解释。
